Heying Pei

Nursing Key Laboratory Of Sichuan Province, State Key Laboratory Of Biotherapy And Cancer Center
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Identification of a ligand-binding site on tubulin mediating the tubulin-RB3 interaction.

Identification of a ligand-binding site on tubulin mediating the tubulin-RB3 interaction.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 11, 2025

Tofacitinib as a Successful Treatment for Hyper-IgE Syndrome and Autoimmunity Associated with Constitutive Activation of JAK3.

Tofacitinib as a Successful Treatment for Hyper-IgE Syndrome and Autoimmunity Associated with Constitutive Activation of JAK3.

Journal: Journal of clinical immunology

Published: March 07, 2025

Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.

Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.

Journal: Signal transduction and targeted therapy

Published: October 02, 2024

Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis.

Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis.

Journal: Journal of medicinal chemistry

Published: August 22, 2024

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms.

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms.

Journal: Blood cancer journal

Published: June 26, 2024

Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.

Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.

Journal: International immunopharmacology

Published: June 18, 2023

Ethanol extract of Piper wallichii ameliorates DSS-induced ulcerative colitis in mice: Involvement of TLR4/NF-κB/COX-2 signaling pathway.

Ethanol extract of Piper wallichii ameliorates DSS-induced ulcerative colitis in mice: Involvement of TLR4/NF-κB/COX-2 signaling pathway.

Journal: Journal of ethnopharmacology

Published: December 31, 2022

Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.

Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.

Journal: Bioorganic chemistry

Published: October 02, 2022

Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition.

Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition.

Journal: Frontiers in pharmacology

Published: July 22, 2022

Small Molecules Promote Selective Denaturation and Degradation of Tubulin Heterodimers through a Low-Barrier Hydrogen Bond.

Small Molecules Promote Selective Denaturation and Degradation of Tubulin Heterodimers through a Low-Barrier Hydrogen Bond.

Journal: Journal of medicinal chemistry

Published: June 28, 2022

Crystal structure of tubulin-barbigerone complex enables rational design of potent anticancer agents with isoflavone skeleton.

Crystal structure of tubulin-barbigerone complex enables rational design of potent anticancer agents with isoflavone skeleton.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: June 21, 2022

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model.

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model.

Journal: Annals of medicine

Published: March 04, 2022

Showing 1-12 of 53

Last Updated: 09/26/2026